JangoBio recently announced its founding as a biotech company focused on restoring hormones to their optimal youthful levels.

The pre-clinical stage company was formed in 2015 and is developing new therapies to sustainably reverse hormone imbalances associated with aging and mitigate the risk of developing a wide range of age-related diseases.

“Our team is leading the way on cell-based therapies for treatment of reproductive hormone imbalance,” JangoBio CEO and Founder Craig Atwood said in a statement. “Dysregulation of key hormones occurs naturally and progressively with aging. Published data support the idea that restoring levels of reproductive hormones to levels seen during youth may also mitigate various age-related conditions, such as Alzheimer’s disease, osteoporosis and type II diabetes.”

According to a release, JangoBio’s therapies will carry none of the risks associated with current hormone therapies and will be substantially more effective.

Atwood also is an University of Wisconsin Department of Medicine associate professor. On the management team, he is joined by Chief Medical Officer George Yu, Chief Operations Officer William Kohl, Chief Financial Officer Dirk Racine and Chief Business Officer Carter Cliff.